8-K: PMGC Holdings Finalizes Divestiture of Elevai Skincare to Carmell Corporation

PMGC Holdings Inc. completes the sale of its Elevai Skincare subsidiary to Carmell Corporation for a combination of stock, cash, and potential earn-out payments.

Summary

• PMGC Holdings Inc. has completed the divestiture of its wholly-owned subsidiary, Elevai Skincare Inc., to Cutis Cura Corporation, a subsidiary of Carmell Corporation (CTCX).
• The deal closed on January 16, 2025, following the asset purchase agreement dated December 31, 2024.
• The purchase price included approximately $1.4 million, consisting of 1,149,226 shares of CTCX common stock, with an additional 117,814 shares held back for indemnification.
• Carmell Corporation also assumed certain liabilities of Elevai and will pay $56,525 in cash after selling specific inventory.
• PMGC is eligible for earn-out consideration, including 5% of net sales from Elevai's existing products over the next five years.
• A one-time payment of $500,000 will be paid if Elevai's hair and scalp products achieve $500,000 in net revenue within 24 months.
• Following the closing, the total number of PMGC common stock outstanding was approximately 3.07 million.
• Pro forma financial statements give effect to the sale as if it occurred on January 1, 2022.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. The divestiture is presented as a strategic move to improve the company's financial position and focus on growth opportunities. However, the reliance on earn-out payments introduces some uncertainty.

Positives

• The divestiture strengthens PMGC's balance sheet.
• The divestiture reduces PMGC's operational losses.
• The deal includes potential future upside through earn-out payments and royalties.
• The divestiture allows PMGC to focus on new opportunities aligned with its long-term vision.
• The company received approximately $1.1 million of Carmell common stock at a price of $0.8488 per share.

Risks

• The earn-out payments are contingent on Carmell's future performance and may not materialize.
• The indemnification holdback of 117,814 shares of Carmell stock could be used to cover potential liabilities.
• The press release contains forward-looking statements that are subject to risks and uncertainties.

Future Outlook

PMGC Holdings intends to use the proceeds from the divestiture to strengthen its balance sheet, reduce operational losses, and pursue new opportunities to maximize shareholder value.

Management Comments

• The sale was executed to maximize immediate financial benefit while securing future upside through structured royalties and milestone payments.
• This strategic Divestiture marks a significant milestone in PMGCs journey as a diversified holding company.

Industry Context

The divestiture reflects a trend of companies streamlining operations to focus on core competencies and improve financial performance. PMGC's move to sell its skincare business aligns with this trend, allowing it to concentrate on its remaining portfolio companies.

Comparison to Industry Standards

• Comparable transactions in the skincare industry often involve a mix of upfront payments and earn-out provisions tied to future performance.
• The 5% royalty on net sales is a fairly standard earn-out structure in similar deals.
• The valuation of Elevai Skincare at approximately $1.4 million is relatively small compared to larger acquisitions in the beauty and personal care sector, such as Estée Lauder's acquisition of DECIEM.

Stakeholder Impact

• Shareholders may benefit from the improved financial position and focus on growth.
• Employees of Elevai Skincare are now employees of Carmell Corporation.
• Customers of Elevai Skincare should see no immediate changes as the business continues under new ownership.

Key Dates